Trade Gyre Therapeutics Inc - GYRE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1168 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 8.5366 |
| Open | 9.0166 |
| 1-Year Change | -42.89% |
| Day's Range | 8.9966 - 9.3166 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | 9.1066 | 0.0400 | 0.44% | 9.0666 | 9.3666 | 8.8766 |
| Apr 22, 2025 | 8.5366 | 0.1100 | 1.31% | 8.4266 | 8.8266 | 8.2166 |
| Apr 21, 2025 | 8.3666 | -0.2500 | -2.90% | 8.6166 | 9.3066 | 8.2166 |
| Apr 17, 2025 | 8.8266 | 0.9600 | 12.20% | 7.8666 | 8.9066 | 7.8666 |
| Apr 16, 2025 | 7.9066 | -0.1900 | -2.35% | 8.0966 | 8.2566 | 7.8166 |
| Apr 15, 2025 | 8.3266 | 0.6800 | 8.89% | 7.6466 | 8.3766 | 7.5966 |
| Apr 14, 2025 | 7.6466 | 0.1600 | 2.14% | 7.4866 | 7.7666 | 7.2766 |
| Apr 11, 2025 | 7.4666 | 0.2000 | 2.75% | 7.2666 | 7.4966 | 6.9966 |
| Apr 10, 2025 | 7.2266 | -0.2800 | -3.73% | 7.5066 | 7.5666 | 6.9766 |
| Apr 9, 2025 | 7.7066 | 0.8600 | 12.56% | 6.8466 | 7.8666 | 6.0666 |
| Apr 8, 2025 | 7.1766 | -0.8000 | -10.03% | 7.9766 | 8.8066 | 7.0166 |
| Apr 7, 2025 | 7.5266 | 0.6400 | 9.29% | 6.8866 | 7.5766 | 6.2266 |
| Apr 4, 2025 | 6.8866 | 0.4000 | 6.17% | 6.4866 | 6.9666 | 6.3166 |
| Apr 3, 2025 | 6.7266 | 0.1800 | 2.75% | 6.5466 | 6.8966 | 6.4666 |
| Apr 2, 2025 | 7.0166 | 0.7700 | 12.33% | 6.2466 | 7.5466 | 6.2466 |
| Apr 1, 2025 | 6.3766 | -1.3100 | -17.04% | 7.6866 | 7.8666 | 6.1366 |
| Mar 31, 2025 | 7.6566 | -1.2300 | -13.84% | 8.8866 | 8.9366 | 6.9566 |
| Mar 28, 2025 | 9.0466 | 0.0700 | 0.78% | 8.9766 | 9.0666 | 8.8066 |
| Mar 27, 2025 | 9.0166 | 0.1600 | 1.81% | 8.8566 | 9.3666 | 8.8566 |
| Mar 26, 2025 | 8.7366 | -0.5600 | -6.02% | 9.2966 | 9.3966 | 8.6166 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Catalyst Biosciences, Inc. Company profile
About Catalyst Biosciences Inc
Catalyst Biosciences, Inc., formerly Targacept, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on medical needs in disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously (SQ) administered engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders in patients with Hemophilia A or B with inhibitors. Its clinical trial of MarzAA in Factor VII Deficiency, Glanzmann Thrombasthenia, and Hemophilia A with inhibitor patients on prophylaxis Hemlibra for treatment of episodic bleeding (MAA-202). The Company pipeline also includes dalcinonacog alfa (DalcA), a subcutaneously (SQ) Factor IX (FIX) to prevent bleeding episodes for Hemophilia B patients. Its discovery stage Factor IX gene therapy construct, CB 2679d-GT for Hemophilia B.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Catalyst Biosciences Inc revenues decreased 74% to $4.9M. Net loss increased 81% to $67.6M. Revenues reflect License decrease from $15.1M to $0K. Higher net loss reflects Research and development increase of 3% to $38.3M (expense), General and administrative - Balancing v increase of 9% to $11.3M (expense), Miscellaneous income (expense) decrease of 99% to $8K (income).
Equity composition
Common Stock $.001 Par, 04/11, 100M auth., 29,021,460 issd., Insiders control approx. 0.08%. IPO: 4/06 5,000,000 shs. @ $9per share by Deutsche Bank Securities. 8/15, 1-for-7 reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
12770 High Bluff Drive, Suite 150
SAN DIEGO
CALIFORNIA 92130
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com